Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC – Get Free Report) have been given an average recommendation of “Hold” by the ten research firms that are covering the company, MarketBeat reports. Nine analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $10.50.
Several equities research analysts have commented on the company. StockNews.com assumed coverage on Revance Therapeutics in a research note on Monday. They issued a “hold” rating on the stock. Piper Sandler cut Revance Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 12th. Barclays restated an “equal weight” rating and issued a $7.00 target price (down previously from $10.00) on shares of Revance Therapeutics in a research note on Friday, September 13th. William Blair restated a “market perform” rating on shares of Revance Therapeutics in a research note on Monday, August 12th. Finally, HC Wainwright cut Revance Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 13th.
View Our Latest Analysis on Revance Therapeutics
Institutional Investors Weigh In On Revance Therapeutics
Revance Therapeutics Stock Performance
Shares of RVNC opened at $5.81 on Monday. The stock has a 50 day simple moving average of $5.33 and a 200 day simple moving average of $4.27. Revance Therapeutics has a 52-week low of $2.30 and a 52-week high of $13.12. The firm has a market capitalization of $606.85 million, a PE ratio of -1.60 and a beta of 1.00.
Revance Therapeutics (NASDAQ:RVNC – Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.48) by $0.12. The business had revenue of $65.39 million during the quarter, compared to analyst estimates of $66.30 million. During the same quarter in the prior year, the firm posted ($0.80) earnings per share. Revance Therapeutics’s revenue for the quarter was up 20.2% compared to the same quarter last year.
About Revance Therapeutics
Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.
See Also
- Five stocks we like better than Revance Therapeutics
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- 3 Stocks That Could Rise on European Bank Interest Rate Cuts
- Dividend Payout Ratio Calculator
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- Insider Trades May Not Tell You What You Think
- MarketBeat Week in Review – 9/16 – 9/20
Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.